<DOC>
	<DOCNO>NCT00360399</DOCNO>
	<brief_summary>This study compare different treatment depression order identify factor predict effectiveness , include companion study investigate combine treatment long term effectiveness .</brief_summary>
	<brief_title>Identifying Factors That Predict Antidepressant Treatment Response</brief_title>
	<detailed_description>Major depressive disorder ( MDD ) serious illness affect person 's body , mood , thought . The symptom MDD interfere person 's ability work , study , sleep , eat , enjoy activity pleasurable . Antidepressant medication psychotherapy among effective treatment MDD . Individuals often respond one type treatment , another . Currently , however , doctor way pre-determining individual benefit treatment . In absence practical predictor MDD treatment response , potential efficacy exist MDD treatment limit . This study identify factor may predict MDD treatment response compare effectiveness selective serotonin reuptake inhibitor ( SSRI ) , serotonin norepinephrine reuptake inhibitor ( SNRI ) , cognitive behavioral therapy people MDD . Participants 14-week , double-blind study randomly assign receive duloxetine ( SNRI ) , escitalopram ( SSRI ) , cognitive behavioral therapy . During first 2 week screen , participant complete questionnaire , clinician evaluation , electrocardiogram , personality assessment , dexamethasone-corticotropin releasing factor test , functional magnetic resonance image scan provide blood sample . Upon completion screening , patient start treatment randomize . Duloxetine escitalopram two medication approve Food Drug Administration treatment depression . Cognitive behavioral therapy talk therapy also use treat depression . All participant assign take duloxetine escitalopram see study physician weekly 6 week , every week remainder study . Participants assign cognitive behavioral therapy attend therapy session twice week first 4 week , week remainder study . The following assessment perform participant visit : vital sign weight measurement ; clinician assessment ; self-report questionnaire . Additionally , blood sample take three visit trial functional magnetic resonance imaging ( fMRI ) scan perform select time . A companion study main CIDAR study offer participant treatment . Participants achieve remission initial 12 week treatment option enroll 21-month follow-up study maintenance treatment , visit every three month monitor sustain response relapse . Participants remit option enroll another 12-week treatment course , receive combination CBT medication . Participants achieve response combination treatment eligible receive maintenance combination treatment additional 18 month , monitor sustain response relapse . Participants wish enroll continue companion study provide referral treatment another mental health provider .</detailed_description>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Current DSMIV diagnosis major depressive episode , determine Structured Clinical Interview DSMIV ( SCIDIV ) Primary diagnosis MDD , base prominence symptom target intervention ( comorbid anxiety disorder , except obsessivecompulsive disorder ( OCD ) , criteria exclusion ) Score least 18 17item Hamilton Rating Scale Depression ( HAMD17 ) Agrees use effective form contraception and/or double barrier method Previously treat major depression either medication psychotherapy Current psychosis , dementia , eat disorder , dissociative disorder History bipolar disorder ( I II ) schizophrenia Alcohol drug dependence within 3 month prior study entry current alcohol drug abuse ( exclude nicotine caffeine ) , assess medical history urine drug screening Requires neuroleptic mood stabilizer therapy addition depression treatment Presence acute chronic medical disorder could affect successful completion trial Medical contraindication would preclude treatment escitalopram duloxetine Presence practical issue would likely prevent completion study ( e.g. , plan geographical relocation ) Pregnant breastfeed Medical condition could prevent safe use MRI ( e.g. , pacemaker , aneurysm clip , neurostimulators , cochlear implant , metal eye , implant ; steel worker ) Medical condition could prevent safe completion dexamethasonecorticotropin release factor ( DexCRF ) test ( e.g. , uncontrolled hypertension , significant abnormality EKG , anemia , know allergy drug )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Escitalopram</keyword>
	<keyword>Duloxetine</keyword>
	<keyword>Cognitive Behavioral Therapy</keyword>
	<keyword>PET</keyword>
	<keyword>fMRI</keyword>
</DOC>